Heart Failure Patients
Could Benefit From Genetic Test - Beta Blockers Work In Some Patients
Only - May Determine Best Treatment
July 10th 2006
Scientists believe they can genetically test patients suffering from
heart failure to determine which ones will benefit from beta-blockers.
Maryland researchers have identified a common genetic variation that
could help determine whether a person with heart failure would benefit
from the common drug.
The study, involving 1040 heart failure patients over a four year
period, compared beta-blocker to a placebo and found a 38 percent
reduction in the death rate among patients who took the beta-blocker and
who also had two copies of a genetic variant called arginine (Arg-389).
They also found that 34 percent of these patients had a reduction in the
combined number of hospitalizations and deaths.
Lead researcher Stephen B. Liggett MD said “For the first time, we have
a genetic test that will help guide us to the best treatment for
individual patients with heart failure and provide what has been called
personal medicine. This personalized therapy, based on genes, gives us
an opportunity to tailor therapy in a way that we really were never able
to do before,”